Melanoma: SWOG E4697 (Iowa Cancer Specialists)

SWOG E4697: Randomized Placebo-Controlled Phase III Trial of Yeast Deriverd GM-CSF vs Peptide Vaccination vs GM-GSF + Peptide Vaccination vs Placebo in Patients with No Evidence of Disease after Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma.

Objective

This research is being done because there currently is no generally agreed upon treatment to prevent melanoma, a type of skin cancer, from coming back. We hope to find a more effective and long lasting treatment for patients with melanoma.

The purpose of this study is to find out if a biological agent, called GM-CSF, stops or delays melanoma from returning. In patients with a cell marker called HLA-A2, we hope to find out if GM-CSF plus a vaccine made against tumor protein fragments stops or delays the skin cancer from returning better than GM-CSF alone.

No treatment (GM-CSF placebo and/or vaccine placebo) is considered the standard treatment for this study.

Principal Investigator(s)
George Kovach

Clinical Trial Categories

  • Cancer
  • Melanoma
Sponsor(s)
SWOG
Contact
Kim Turner, R.N. at 563-421-1908
or turnerk@genesishealth.com

Location

  • Cancer Care Institute
    1351 West Central Park
    Pavilion 1, 1st Floor
    Davenport, IA 52804
    Main: 563-421-1900
    Alternate: 800-446-6088
    Fax: 563-421-1938

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email